-

VRT Shareholder Class Action: Robbins LLP Reminds Investors of Class Action Against Vertiv Holdings Co. (VRT)

SAN DIEGO--(BUSINESS WIRE)--The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Vertiv Holdings Co. (NYSE: VRT) securities between April 28, 2021 and February 23, 2022, for violations of the Securities Exchange Act of 1934. Vertiv purports to be a “global leader in the design, manufacturing and servicing of critical digital infrastructure technology that powers, cools, deploys, secures and maintains electronics that process, store and transmit data.”

If you would like more information about Vertiv Holdings Co.'s misconduct, click here.

What is this Case About: Vertiv Holdings Co.'s (VRT) Failed to Disclose that it Would be Impacted by Inflation and Supply Chain Restraints

According to the complaint, throughout the class period, defendants noted strong net sales growth and increased profits. On April 28, 2021, the Company increased its full year 2021 adjusted operating profit guidance, which purportedly included "the expected negative net impact in the remainder of the year of higher commodity and freight costs." On October 27, 2021, the Company reported an increase in net sales growth. Though supply chain issues continued, the Company acknowledged, "[c]ost containment actions have been accelerated heading into our fourth quarter to mitigate impacts from increased supply chain disruptions."

These statements proved to be false. Defendants failed to disclose to investors that the Company could not adequately respond to supply chain issues and inflation by increasing its prices, and that as a result of increasing costs, Vertiv's earnings would be adversely impacted.

On February 23, 2022, Vertiv reported disappointing financial results. Vertiv's CEO attributed the poor results to management "consistently underestimate[ing] inflation and supply chain constraints for both timing and degree, which dictated a tepid 2021 pricing response." On this news, the Company's stock price fell $7.19, or 37%, to close at $12.38 per share on February 23, 2022.

Next Steps: If you acquired shares of Vertiv Holdings Co. (VRT) between April 28, 2021 and February 23, 2022, you have until May 23, 2022, to ask the court to appoint you lead plaintiff for the class. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Vertiv Holdings Co. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:VRT

Release Summary
Vertiv Holdings Co.'s (VRT) Failed to Disclose that it Would be Impacted by Inflation and Supply Chain Restraints
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Soleno Therapeutics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025. Soleno is a pharmaceutical company focused on developing therapies for rare diseases. The Company’s only commercial product is diazoxide choline extended-release tablets (“DCCR”) for the treatment of hyperphagia in individuals afflicted with Prader-Wil...

Investor Notice: Robbins LLP Informs Investors of the Eos Energy Enterprises, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Eos Energy Enterprises, Inc. (NASDAQ: EOSE) securities between November 5, 2025 and February 26, 2026. Eos Energy designs, manufactures, and markets zinc-based battery energy storage systems intended for utility-scale commercial and industrial applications. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...

Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. The Company’s lead product candidate is rezpegaldesleukin (a/k/a REZPEG or NKTR-358), a n...
Back to Newsroom